ESTRO meets Asia 2024 - Abstract Book

S182

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

Abbreviations: KPS=Karnofsky performance status;

Staging has been done as per AJCC 8 th edition

Table-1 is showing patents characteristics. All patients were p16 negative. The median radiotherapy (RT) dose was 70Gy (range 66-70). 30 patients received ≥ 5 cycles of concurrent chemotherapy. The median cumulative cisplatin dose was 405 mg (range 260-560). Median follow-up duration was 49 months (range3-61). The crude complete response (CR) rate, partial response rate and progression rates were 82.35%, 14.7% and 2.94% respectively at 3 months after completion of radiotherapy. CR rate was 100%, 84.2% and 40% for patients of larynx, oropharynx and hypopharynx respectively. Median S1, S2, S3 and S4 levels were 212.39ng/ml (range31.43-660.82), 135.56ng/ml (range17.75-722.99), 119.04ng/ml (range15.12-583.5) and 100.27ng/ml (range19.65-1043.76) respectively. Declining trend in cfDNA levels was seen from S1 to S4 in all patients who had CR (figure-1). 4 of 28 patients having CR had increased S3 levels vs S1. 5 of 6 patients having non-CR had increased S3 levels from S1. The median difference between S3 and S1 for the entire cohort was -73.6 ng/ml (range -480.6 – 186.2). Spearman correlation coefficient between S3-S1 and response (CR vs non-CR) was 0.48 (p = 0.004).

Conclusion:

Moderate positive correlation was found between change in cfDNA levels (between initial and mid-RT) and tumour response in LAHNSCC treated with chemoradiotherapy. A decline in cfDNA levels midway through RT could potentially indicate a complete response to chemoradiotherapy. Since forecasting treatment response during the middle of the RT proves challenging through conventional radiological or clinical assessments, cfDNA may be a promising predictive biomarker for tailoring personalized treatment strategies.

Keywords: circulating free DNA, head and neck cancer

296

Digital Poster

Study Evaluating The Salivary Flow To TENS Therapy In Carcinoma Head And Neck Patients On Radiation

Sofia Rajesh Loganathan 1 , Narkis Banu 2

1 Radiation Oncology, GVN Cancer Institute, Tiruchirappalli, India. 2 Physiotherapy, GVN Cancer Institute, Tiruchirappalli, India

Purpose/Objective:

XEROSTOMIA IS ONE OF THE ACUTE AND LATE COMPLICATION OF RADIATION THERAPY IN CARCINOMA HEAD AND NECK PATIENTS. THIS AFFECTS THE QUALITY OF LIFE AFTER RECOVERING FROM THE DISEASE. TENS – TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION IS A PHYSICAL THERAPY USED FOR PAIN RELIEF IN ORTHOPAEDIC PATIENTS HAVE BEEN PROVEN IN FEW EARLIER STUDIES TO BENEFIT IN XEROSTOMIA CAUSED BY CONNECTIVE TISSUE DISORDERS.